Artemisinin resistance: current status and scenarios for containment

Key Points Malaria, caused by Plasmodium spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease. Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial. Owing...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Microbiology 2010-04, Vol.8 (4), p.272-280
Hauptverfasser: Dondorp, Arjen M., Yeung, Shunmay, White, Lisa, Nguon, Chea, Day, Nicholas P.J., Socheat, Duong, von Seidlein, Lorenz
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 280
container_issue 4
container_start_page 272
container_title Nature reviews. Microbiology
container_volume 8
creator Dondorp, Arjen M.
Yeung, Shunmay
White, Lisa
Nguon, Chea
Day, Nicholas P.J.
Socheat, Duong
von Seidlein, Lorenz
description Key Points Malaria, caused by Plasmodium spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease. Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial. Owing to the use of artemisinin as a monotherapy, strains of Plasmodium falciparum have emerged that have a decreased sensitivity to the drug. Several strategies to prevent the spread of the less resistant parasites have been put in place, such as a multifaceted approach that includes early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening of management and surveillance systems, and operations research. Other, broader strategies can target the emergence and spread of drug resistance. These include mass drug administration, using multiple first-line therapies simultaneously, surveillance, active case investigation and focal control Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen Dondorp and colleagues describe the initial detection of artemisinin resistance and discuss several strategies to prevent its spread. Artemisinin combination therapies are the first-line treatments for uncomplicated Plasmodium falciparum malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant P. falciparum malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment.
doi_str_mv 10.1038/nrmicro2331
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_744704898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A222252169</galeid><sourcerecordid>A222252169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-6aab9c2fcd978f2fd51a7101426f1f7cfddadd0101f54240b4d97a3322c0789e3</originalsourceid><addsrcrecordid>eNqF0U1PwyAYB3BiNE6nJ--m0YMHncIDlNbbMl-TJV70TBiFhWWlE9qD316WzmmMiVx4--Xh5Y_QCcHXBNPixofa6dAApWQHHRDB8Ihwyna3Y8gH6DDGBcbAuYB9NAAMuOAcH6C7cWhN7aLzzmfBRBdb5bW5zXQXgvFtluZtFzPlqyxq41VwTcxsEzLd-FY5Xyd0hPasWkZzvOmH6O3h_nXyNJq-PD5PxtORZgTaUa7UrNRgdVWKwoKtOFGCYMIgt8QKbatKVRVOK5YzYHjGElSUAmgsitLQIbro665C896Z2Mp0c22WS-VN00UpGBOYFWXxv6RUkJynfxqis19y0XTBp2dIAJYzmuM1Ou_RXC2NdN42bVB6XVKOITUOJC-TuuxVSiPGYKxcBVer8CEJluuo5I-okj7dHNzNalNt7Vc2CVz1IKYtPzfh-2Z_1fsEWw-d5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>224643605</pqid></control><display><type>article</type><title>Artemisinin resistance: current status and scenarios for containment</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><creator>Dondorp, Arjen M. ; Yeung, Shunmay ; White, Lisa ; Nguon, Chea ; Day, Nicholas P.J. ; Socheat, Duong ; von Seidlein, Lorenz</creator><creatorcontrib>Dondorp, Arjen M. ; Yeung, Shunmay ; White, Lisa ; Nguon, Chea ; Day, Nicholas P.J. ; Socheat, Duong ; von Seidlein, Lorenz</creatorcontrib><description>Key Points Malaria, caused by Plasmodium spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease. Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial. Owing to the use of artemisinin as a monotherapy, strains of Plasmodium falciparum have emerged that have a decreased sensitivity to the drug. Several strategies to prevent the spread of the less resistant parasites have been put in place, such as a multifaceted approach that includes early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening of management and surveillance systems, and operations research. Other, broader strategies can target the emergence and spread of drug resistance. These include mass drug administration, using multiple first-line therapies simultaneously, surveillance, active case investigation and focal control Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen Dondorp and colleagues describe the initial detection of artemisinin resistance and discuss several strategies to prevent its spread. Artemisinin combination therapies are the first-line treatments for uncomplicated Plasmodium falciparum malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant P. falciparum malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment.</description><identifier>ISSN: 1740-1526</identifier><identifier>EISSN: 1740-1534</identifier><identifier>DOI: 10.1038/nrmicro2331</identifier><identifier>PMID: 20208550</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/326/22/1294 ; 631/326/417 ; 639/705 ; 692/699/255/1629 ; Antimalarials - therapeutic use ; Antiparasitic agents ; Artemisinins - chemistry ; Artemisinins - therapeutic use ; Biomedical and Life Sciences ; Cambodia ; Care and treatment ; Causes of ; Containment ; Diagnosis ; Disease Outbreaks - prevention &amp; control ; Drug dosages ; Drug Resistance ; Drug resistance in microorganisms ; Drug therapy ; Genetic aspects ; Health aspects ; Infectious Diseases ; Life Sciences ; Malaria ; Malaria, Falciparum - drug therapy ; Malaria, Falciparum - epidemiology ; Medical Microbiology ; Medicine ; Microbiology ; Parasites ; Parasitology ; Plasmodium falciparum ; Plasmodium falciparum - pathogenicity ; review-article ; Sesquiterpenes ; Thailand ; Vector-borne diseases ; Virology</subject><ispartof>Nature reviews. Microbiology, 2010-04, Vol.8 (4), p.272-280</ispartof><rights>Springer Nature Limited 2010</rights><rights>COPYRIGHT 2010 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Apr 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-6aab9c2fcd978f2fd51a7101426f1f7cfddadd0101f54240b4d97a3322c0789e3</citedby><cites>FETCH-LOGICAL-c412t-6aab9c2fcd978f2fd51a7101426f1f7cfddadd0101f54240b4d97a3322c0789e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrmicro2331$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrmicro2331$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20208550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dondorp, Arjen M.</creatorcontrib><creatorcontrib>Yeung, Shunmay</creatorcontrib><creatorcontrib>White, Lisa</creatorcontrib><creatorcontrib>Nguon, Chea</creatorcontrib><creatorcontrib>Day, Nicholas P.J.</creatorcontrib><creatorcontrib>Socheat, Duong</creatorcontrib><creatorcontrib>von Seidlein, Lorenz</creatorcontrib><title>Artemisinin resistance: current status and scenarios for containment</title><title>Nature reviews. Microbiology</title><addtitle>Nat Rev Microbiol</addtitle><addtitle>Nat Rev Microbiol</addtitle><description>Key Points Malaria, caused by Plasmodium spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease. Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial. Owing to the use of artemisinin as a monotherapy, strains of Plasmodium falciparum have emerged that have a decreased sensitivity to the drug. Several strategies to prevent the spread of the less resistant parasites have been put in place, such as a multifaceted approach that includes early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening of management and surveillance systems, and operations research. Other, broader strategies can target the emergence and spread of drug resistance. These include mass drug administration, using multiple first-line therapies simultaneously, surveillance, active case investigation and focal control Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen Dondorp and colleagues describe the initial detection of artemisinin resistance and discuss several strategies to prevent its spread. Artemisinin combination therapies are the first-line treatments for uncomplicated Plasmodium falciparum malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant P. falciparum malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment.</description><subject>631/326/22/1294</subject><subject>631/326/417</subject><subject>639/705</subject><subject>692/699/255/1629</subject><subject>Antimalarials - therapeutic use</subject><subject>Antiparasitic agents</subject><subject>Artemisinins - chemistry</subject><subject>Artemisinins - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Cambodia</subject><subject>Care and treatment</subject><subject>Causes of</subject><subject>Containment</subject><subject>Diagnosis</subject><subject>Disease Outbreaks - prevention &amp; control</subject><subject>Drug dosages</subject><subject>Drug Resistance</subject><subject>Drug resistance in microorganisms</subject><subject>Drug therapy</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Infectious Diseases</subject><subject>Life Sciences</subject><subject>Malaria</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Malaria, Falciparum - epidemiology</subject><subject>Medical Microbiology</subject><subject>Medicine</subject><subject>Microbiology</subject><subject>Parasites</subject><subject>Parasitology</subject><subject>Plasmodium falciparum</subject><subject>Plasmodium falciparum - pathogenicity</subject><subject>review-article</subject><subject>Sesquiterpenes</subject><subject>Thailand</subject><subject>Vector-borne diseases</subject><subject>Virology</subject><issn>1740-1526</issn><issn>1740-1534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0U1PwyAYB3BiNE6nJ--m0YMHncIDlNbbMl-TJV70TBiFhWWlE9qD316WzmmMiVx4--Xh5Y_QCcHXBNPixofa6dAApWQHHRDB8Ihwyna3Y8gH6DDGBcbAuYB9NAAMuOAcH6C7cWhN7aLzzmfBRBdb5bW5zXQXgvFtluZtFzPlqyxq41VwTcxsEzLd-FY5Xyd0hPasWkZzvOmH6O3h_nXyNJq-PD5PxtORZgTaUa7UrNRgdVWKwoKtOFGCYMIgt8QKbatKVRVOK5YzYHjGElSUAmgsitLQIbro665C896Z2Mp0c22WS-VN00UpGBOYFWXxv6RUkJynfxqis19y0XTBp2dIAJYzmuM1Ou_RXC2NdN42bVB6XVKOITUOJC-TuuxVSiPGYKxcBVer8CEJluuo5I-okj7dHNzNalNt7Vc2CVz1IKYtPzfh-2Z_1fsEWw-d5g</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Dondorp, Arjen M.</creator><creator>Yeung, Shunmay</creator><creator>White, Lisa</creator><creator>Nguon, Chea</creator><creator>Day, Nicholas P.J.</creator><creator>Socheat, Duong</creator><creator>von Seidlein, Lorenz</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BKSAR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PCBAR</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>F1W</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope></search><sort><creationdate>20100401</creationdate><title>Artemisinin resistance: current status and scenarios for containment</title><author>Dondorp, Arjen M. ; Yeung, Shunmay ; White, Lisa ; Nguon, Chea ; Day, Nicholas P.J. ; Socheat, Duong ; von Seidlein, Lorenz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-6aab9c2fcd978f2fd51a7101426f1f7cfddadd0101f54240b4d97a3322c0789e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>631/326/22/1294</topic><topic>631/326/417</topic><topic>639/705</topic><topic>692/699/255/1629</topic><topic>Antimalarials - therapeutic use</topic><topic>Antiparasitic agents</topic><topic>Artemisinins - chemistry</topic><topic>Artemisinins - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Cambodia</topic><topic>Care and treatment</topic><topic>Causes of</topic><topic>Containment</topic><topic>Diagnosis</topic><topic>Disease Outbreaks - prevention &amp; control</topic><topic>Drug dosages</topic><topic>Drug Resistance</topic><topic>Drug resistance in microorganisms</topic><topic>Drug therapy</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Infectious Diseases</topic><topic>Life Sciences</topic><topic>Malaria</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Malaria, Falciparum - epidemiology</topic><topic>Medical Microbiology</topic><topic>Medicine</topic><topic>Microbiology</topic><topic>Parasites</topic><topic>Parasitology</topic><topic>Plasmodium falciparum</topic><topic>Plasmodium falciparum - pathogenicity</topic><topic>review-article</topic><topic>Sesquiterpenes</topic><topic>Thailand</topic><topic>Vector-borne diseases</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dondorp, Arjen M.</creatorcontrib><creatorcontrib>Yeung, Shunmay</creatorcontrib><creatorcontrib>White, Lisa</creatorcontrib><creatorcontrib>Nguon, Chea</creatorcontrib><creatorcontrib>Day, Nicholas P.J.</creatorcontrib><creatorcontrib>Socheat, Duong</creatorcontrib><creatorcontrib>von Seidlein, Lorenz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Earth, Atmospheric &amp; Aquatic Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Earth, Atmospheric &amp; Aquatic Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 1: Biological Sciences &amp; Living Resources</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) 3: Aquatic Pollution &amp; Environmental Quality</collection><collection>Aquatic Science &amp; Fisheries Abstracts (ASFA) Professional</collection><jtitle>Nature reviews. Microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dondorp, Arjen M.</au><au>Yeung, Shunmay</au><au>White, Lisa</au><au>Nguon, Chea</au><au>Day, Nicholas P.J.</au><au>Socheat, Duong</au><au>von Seidlein, Lorenz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Artemisinin resistance: current status and scenarios for containment</atitle><jtitle>Nature reviews. Microbiology</jtitle><stitle>Nat Rev Microbiol</stitle><addtitle>Nat Rev Microbiol</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>8</volume><issue>4</issue><spage>272</spage><epage>280</epage><pages>272-280</pages><issn>1740-1526</issn><eissn>1740-1534</eissn><abstract>Key Points Malaria, caused by Plasmodium spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease. Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial. Owing to the use of artemisinin as a monotherapy, strains of Plasmodium falciparum have emerged that have a decreased sensitivity to the drug. Several strategies to prevent the spread of the less resistant parasites have been put in place, such as a multifaceted approach that includes early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening of management and surveillance systems, and operations research. Other, broader strategies can target the emergence and spread of drug resistance. These include mass drug administration, using multiple first-line therapies simultaneously, surveillance, active case investigation and focal control Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen Dondorp and colleagues describe the initial detection of artemisinin resistance and discuss several strategies to prevent its spread. Artemisinin combination therapies are the first-line treatments for uncomplicated Plasmodium falciparum malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant P. falciparum malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>20208550</pmid><doi>10.1038/nrmicro2331</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1740-1526
ispartof Nature reviews. Microbiology, 2010-04, Vol.8 (4), p.272-280
issn 1740-1526
1740-1534
language eng
recordid cdi_proquest_miscellaneous_744704898
source MEDLINE; Springer Nature - Complete Springer Journals; Nature
subjects 631/326/22/1294
631/326/417
639/705
692/699/255/1629
Antimalarials - therapeutic use
Antiparasitic agents
Artemisinins - chemistry
Artemisinins - therapeutic use
Biomedical and Life Sciences
Cambodia
Care and treatment
Causes of
Containment
Diagnosis
Disease Outbreaks - prevention & control
Drug dosages
Drug Resistance
Drug resistance in microorganisms
Drug therapy
Genetic aspects
Health aspects
Infectious Diseases
Life Sciences
Malaria
Malaria, Falciparum - drug therapy
Malaria, Falciparum - epidemiology
Medical Microbiology
Medicine
Microbiology
Parasites
Parasitology
Plasmodium falciparum
Plasmodium falciparum - pathogenicity
review-article
Sesquiterpenes
Thailand
Vector-borne diseases
Virology
title Artemisinin resistance: current status and scenarios for containment
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A52%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Artemisinin%20resistance:%20current%20status%20and%20scenarios%20for%20containment&rft.jtitle=Nature%20reviews.%20Microbiology&rft.au=Dondorp,%20Arjen%20M.&rft.date=2010-04-01&rft.volume=8&rft.issue=4&rft.spage=272&rft.epage=280&rft.pages=272-280&rft.issn=1740-1526&rft.eissn=1740-1534&rft_id=info:doi/10.1038/nrmicro2331&rft_dat=%3Cgale_proqu%3EA222252169%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=224643605&rft_id=info:pmid/20208550&rft_galeid=A222252169&rfr_iscdi=true